Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Silmitasertib (sodium salt)

Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.

Product Specifications

CAS Number

[1309357-15-0]

Product Name Alternative

CX-4945 (sodium salt)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Casein Kinase

Type

Reference compound

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/CX-4945-sodium-salt.html

Concentration

10mM

Purity

99.92

Solubility

DMSO : 87.5 mg/mL (ultrasonic) |H2O : 16.67 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=C2C3=C(C(NC4=CC=CC(Cl)=C4)=NC2=C1)C=CN=C3)O[Na]

Molecular Formula

C19H11ClN3NaO2

Molecular Weight

371.75

Precautions

H302, H315, H319, H335

References & Citations

[1]Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
 Cancer Res. 2010 Dec 15;70 (24) :10288-98.|[2]Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7 (2) :1323-40.|[3]Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.|[4]Kendall JJ, et al. CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin. Oncotarget. 2016 Aug 16;7 (33) :53191-53203.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Phase 2

Isoform

CK2

Citation 01

Cancer Cell Int. 2024 Dec 26;24 (1) :432.|Int J Mol Sci. 2021 Jan 15;22 (2) :819.|Metabolism. 2024 Nov 7:162:156060.|Oncotarget. 2016 Aug 16;7 (33) :53191-53203.|Autophagy. 2025 Jan;21 (1) :178-190.|Biochem Biophys Res Commun. 2020 Oct 20;531 (3) :409-415.|Biochem Pharmacol. 2025 Apr 8:116933.|Biomed Pharmacother. 2024 Jul 29:178:117191.|bioRxiv. 2023 Oct 23:2023.10.20.563266.|bioRxiv. 2024 Jul 25:2024.07.25.605073.|bioRxiv. 2024 Nov 6:2024.11.04.621884.|bioRxiv. 2025 April 09.|bioRxiv. 2025 February 07.|bioRxiv. 2025 Sep 26:2025.09.24.677357.|Cancer Biol Ther. 2025 Dec;26 (1) :2457777.|Cancers (Basel) . 2021 Mar 5;13 (5) :1127.|Cell Death Dis. 2024 Mar 16;15 (3) :223.|Cell Death Discov. 2024 Apr 22;10 (1) :185.|Cell Mol Biol Lett. 2023 Oct 24;28 (1) :85.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Rep. 2023 Apr 3;42 (4) :112339.|Cell Stem Cell. 2023 Apr 6;30 (4) :450-459.e9.|Cells. 2021 Jan 18;10 (1) :181.|Drug Res (Stuttg) . 2024 Apr;74 (4) :187-190.|Electronic Theses and Dissertations. 2023 Jul.|EMBO Mol Med. 2020 Aug 7;12 (8) :e11987.|Heliyon. 2024 Aug 18;10 (16) :e36205.|Immunol Cell Biol. 2025 Jan;103 (1) :73-92.|Int J Biol Macromol. 2024 Dec 2:138305.|Int J Mol Sci. 2020 Mar 3;21 (5) :1718.|Invest Ophthalmol Vis Sci. 2022 Dec 1;63 (13) :14.|iScience. 2025 Jan 7;28 (2) :111765.|J Biol Chem. 2024 Nov;300 (11) :107848.|J Immunol. 2023 May 1;210 (9) :1396-1407.|J Med Chem. 2023 Mar 23;66 (6) :4009-4024.|J Med Chem. 2023 Mar 23;66 (6) :4106-4130.|Nat Cell Biol. 2021 Mar;23 (3) :257-267.|Nat Commun. 2023 Feb 9;14 (1) :731.|Nat Commun. 2024 Oct 16;15 (1) :8912.|Nat Plants. 2025 Aug;11 (8) :1572-1590.|Oncogene. 2017 Aug 24;36 (34) :4943-4950.|Oncogene. 2022 Jan;41 (4) :571-585.|Oncol Rep. 2017 Feb;37 (2) :1141-1147. |Patent. US20180263995A1.|Patent. US20250228978A1.|PLoS Pathog. 2025 Sep 10;21 (9) :e1013464.|Research Square Preprint. 2023 May 26.|Research Square Preprint. 2023 Oct 27.|Sci Rep. 2025 Jul 1;15 (1) :20922.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Science. 2017 Dec 1;358 (6367) :eaan4368.|Signal Transduct Target Ther. 2023 May 10;8 (1) :183.|University of California. 2023 Feb.|University of Concepcion. 2023.|University of Washington. 2025.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Guanyl Urea Sulfate
TRC-G844500-10G 10 g

Guanyl Urea Sulfate

Ask
View Details
COMMD2 Human qPCR Template Standard (NM_016094)
HK202109 1 Kit

COMMD2 Human qPCR Template Standard (NM_016094)

Ask
View Details
Anti Desvenlafaxine Pab
165539 100 µg

Anti Desvenlafaxine Pab

Ask
View Details
RO27-3225 TFA
MBS5813380 Inquire

RO27-3225 TFA

Ask
View Details